Undifferentiated connective tissue disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]

The pharmacologic medical therapy is recommended based on the rheumatic disease pattern manifested by the patient such as methotrexate in those exhibiting arthritis and dermatitis. Supportive therapy includes; avoiding cold exposure in those experiencing Raynaud’s phenomenon, avoiding sun in photosensitivity, non-steroidal anti-inflammatory drugs for pain control, sunscreen used for photosensitivity, and emollients for dry skin and rash.

• Avoiding cold exposure in those experiencing Raynaud’s phenomenon
• Avoiding sun in photosensitivity

• Non-steroidal anti-inflammatory drugs for pain control
• Sunscreen used for photosensitivity
• Emollients for dry skin, rash

• Oral regimen
  • Preferred regimen (1): Methotrexate 7.5 mg PO q24h for 6 months (not used for CNS symptoms or serositis)^[1]
    • Dose can be gradually increased to 13.6 mg after 6 months

Template:WH Template:WS